Adenocarcinoma de pulmón diseminado de difícil manejo

  1. López González, J.L.
  2. Navarro Expósito, F.
  3. Losada, C.
  4. Castillo, C.
  5. Álvarez-Mon Soto, M.
Aldizkaria:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Argitalpen urtea: 2017

Zenbakien izenburua: Enfermedades oncológicas (I) Cáncer de pulmón. Cáncer de cabeza y cuello

Saila: 12

Zenbakia: 31

Orrialdeak: 1887-1888

Mota: Artikulua

DOI: 10.1016/J.MED.2017.04.009 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado

Garapen Iraunkorreko Helburuak

Erreferentzia bibliografikoak

  • Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol. 2012; 30:3330.
  • Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17:2081.
  • Marks LB, Yorke ED, Jackson A. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S.
  • National Comprehensive Cancer Network® (NCCN), Clinical Practice Guidelines in Oncology™: non small cell lung cancer.
  • Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt W, Poddubskaya E . Nivolumab versus docetaxel in advanced squamous-cell non small cell lung cancer. N Engl J Med. 2015;373:123.
  • Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Ji-Youn Han. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non small cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540.
Datuen iturria: Dialnet